Could This Biotech Stock Double in 2016?

On a global scale, more than 46 million people now suffer from some form of dementia, and the costs are truly mind-boggling: $818 BILLION today! That’s the annual price of care, medicine, and the cost of lost wages…

By 2030, that $818 BILLION annual problem could grow to an estimated $2 TRILLION problem! Analysts are now saying that a successful drug for this memory-robbing disease could rake in $20 BILLION in sales annually.


As I’m about to show you… we’re in the midst of a total industry reboot in the science of the brain. This renewed scientific focus — measured in the billions of dollars – is leading to crucial new breakthroughs in the understanding and potential treatment of complex brain diseases such as Alzheimer’s and Parkinson’s.

A cure for these and other serious brain disorders may be just around the corner! And that’s why every investor needs to be taking a close look at what tiny CANTABio Pharmaceuticals ( Stock Symbol: CTBO ; website: ) is accomplishing in the realm of Alzheimer’s disease and Parkinson’s disease.

Already with two major research grants under its belt from the Michael J. Fox Foundation, with initial research conducted in conjunction with the famed Rochet Laboratory at Purdue University and industrial partner NovAlix, CANTABio ( CTBO ) could very well beat Big-Pharma to the cure, save millions of lives, and make early investors immensely rich in the process!

CTBO is taking the neurodegenerative disease market by storm by securing the pole-position over the industry’s major players.

Did you miss out one of the biggest biotech IPOs in 2015?
Last summer, on July 11, 2015, investors witnessed one of the largest-ever IPO’s for the biotechnology sector: Axovant Sciences (AXON). Quite literally catching the market off-guard, Axovant was able to sell 21 Million shares at $15 apiece — raising an eye-popping $315 Million at a $1.4 Billion valuation. On the first day of trading, the stock nearly doubled giving Axovant a market capitalization of nearly $3 Billion.

Yet, while this IPO-for-the-ages confirms the immense appetite the market currently has for Alzheimer’s focused companies – a highly positive indicator for early CTBO investors, it also underpins the aforementioned warning signs of investing in “single-drug-focused” biotech companies.

The biotech market is Booming! What does that mean for CTBO?
The biotech sector is well-known for delivering massive gains giving us some of the biggest winners on Wall Street.

In fact, it’s not uncommon for a biotech company to go from relative unknown status and zero revenues to $ Billions in market value in near overnight fashion. It’s the nature of the game for biotechs. The majority of biotech companies start off as primarily research and development firms with little or no revenues. Then RESEARCH leads to discovery → DISCOVERY leads to clinical trials → CLINICAL TRIALS lead to breakthrough drugs that can be brought to the global marketplace to the delight of early shareholders.

Cantabio website: here
Stock quote: CTBO

How To Get Started:

1. Watch the video in the begining of this article, check company’s website and stock quote. It will give you complete understanding about biotech market and investment trends.
2. Make sure you have a stock broker. If you don’t already have one, you can look at these 3 below. :








Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor.
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at; readers can review all public filings by the Company at the SEC’s EDGAR page. is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.